Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | UNG | P13051 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15251878 | 0.85 | MAPT (0.62) | KMT2ATP53CYP1A2MAPTHTT | |
| SCHEMBL21221823 | 0.83 | P2RX3 (0.52) | UNGMAPTHTT | |
| SCHEMBL21221784 | 0.79 | MRGPRX4 (0.56) | SMN1; SMN2TP53UNG | |
| SCHEMBL21221811 | 0.78 | TP53 (0.61) | TP53MAPTHTT | |
| SCHEMBL5298937 | 0.78 | TP53 (0.71) | KMT2ASMN1; SMN2TP53MAPTHTT | |
| SCHEMBL5309531 | 0.76 | TP53 (0.63) | TP53MAPTHTT | |
| SCHEMBL1505883 | 0.75 | MEN1 (0.64) | TSHRMAPK1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5311067 | 0.74 | TP53 (0.69) | TP53MAPTHTT | |
| SCHEMBL21221737 | 0.73 | UNG (0.55) | TP53UNG | |
| SCHEMBL17057465 | 0.72 | TP53 (1.00) | TP53MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853276-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | The Brighamn and Women's Hospital, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006089221-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-24 | — | — | WO | claimed |
| EP-1853276-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | The Brighamn and Women's Hospital, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| WO-2006089221-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | SOD1, SOD3, CAT | USP2 912/4885TSHR 4665/4885MAPK1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.